[{"Physician_Profile_ID": "256009", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Merck Sharp & Dohme Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000053", "Total_Amount_of_Payment_USDollars": "429.10", "Date_of_Payment": "11/11/2013", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "24490852", "Name_of_Associated_Covered_Drug_or_Biological1": "EMEND for Injection", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of In", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "256009", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Valeant Pharmaceuticals North America LLC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010935", "Total_Amount_of_Payment_USDollars": "295.00", "Date_of_Payment": "04/24/2015", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "294351806", "Name_of_Associated_Covered_Drug_or_Biological1": "PROVENGE", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "A REGISTRY OF SIPULEUCEL-T THERAPY IN MEN WITH ADVANCED PROSTATE CANCER", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "256009", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Valeant Pharmaceuticals North America LLC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010935", "Total_Amount_of_Payment_USDollars": "295.00", "Date_of_Payment": "08/13/2015", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "294351810", "Name_of_Associated_Covered_Drug_or_Biological1": "PROVENGE", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "A REGISTRY OF SIPULEUCEL-T THERAPY IN MEN WITH ADVANCED PROSTATE CANCER", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "256009", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Valeant Pharmaceuticals North America LLC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010935", "Total_Amount_of_Payment_USDollars": "295.00", "Date_of_Payment": "12/10/2015", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "294351814", "Name_of_Associated_Covered_Drug_or_Biological1": "PROVENGE", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "A REGISTRY OF SIPULEUCEL-T THERAPY IN MEN WITH ADVANCED PROSTATE CANCER", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "256009", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Merck Sharp & Dohme Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000053", "Total_Amount_of_Payment_USDollars": "85.82", "Date_of_Payment": "10/11/2013", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "24490884", "Name_of_Associated_Covered_Drug_or_Biological1": "EMEND for Injection", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of In", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "256009", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Merck Sharp & Dohme Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000053", "Total_Amount_of_Payment_USDollars": "81.48", "Date_of_Payment": "10/11/2013", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "24490853", "Name_of_Associated_Covered_Drug_or_Biological1": "EMEND for Injection", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of In", "Research_Information_Link": "", "Context_of_Research": ""}]